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Since the original publication (in 1995) of the American HeartAssociation (AHA) consensus statement on secondary pre-
vention, which was endorsed by the American College of
Cardiology (ACC), important evidence from clinical trials has
emerged that further supports the merits of aggressive risk
reduction therapies for patients with atherosclerotic cardiovas-
cular disease. As noted in that statement, aggressive risk factor
management clearly improves patient survival, reduces recurrent
events and the need for interventional procedures, and improves
the quality of life for these patients.
The compelling evidence from recent clinical trials was the
impetus to revise the 1995 guidelines (Table). As examples,
the many lipid reduction trials have generated significant
changes in the National Heart, Lung, and Blood Institute’s
Adult Treatment Panel III report. This report further defined
target cholesterol levels, expanded indications for drug treat-
ment, and initiated therapy earlier. Accumulating b-blocker
data have resulted in broader indications for a larger patient
group. The Heart Outcomes Prevention Evaluation (HOPE)
trial has demonstrated the benefit of ACE inhibitor therapy in
high-risk patients with cardiovascular disease without a
history of an acute event. Further data from ongoing trials
should provide insight into the potential benefits of treating
lower risk patients with combined therapies. The Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events (CAP-
RIE) trial has provided evidence for clopidogrel benefit in
certain patients. Diabetes management recommendations
have been updated to include recent guidelines from the
American Diabetes Association for risk factor management
of diabetics and the growing body of evidence showing
diabetics at high risk for cardiovascular events. The Heart and
Estrogen/progestin Replacement Study (HERS) documented
that hormone replacement therapy is ineffective for second-
ary prevention. The writing group revising this document also
considered other important trials and reports, and they are
included in the selected reading list.
In the 6 years since the guidelines were first published, 2
other developments have made them even more important in
clinical care: the aging of the population continues to expand
the number of patients living with a diagnosis of cardiovas-
cular disease (now estimated at 12.4 million), and the
multiple studies of the actual use of these recommended
therapies in appropriate patients, while showing slow im-
provement, have continued to support the discouraging con-
clusion that a large proportion of patients in whom therapies
are indicated are not receiving those therapies in actual
clinical practice. The AHA and ACC continue to urge that all
medical care settings in which these patients are managed
organize a specific plan to identify appropriate patients,
provide practitioners with useful reminder clues based on the
guidelines, and continuously assess the success achieved in
providing all appropriate therapies to all of the patients who
can benefit from them.
Selected Reading
1. Adult Treatment Panel III. Executive summary of the third report of the
National Cholesterol Education Program (NCEP) Expert Panel on
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AHA/ACC Secondary Prevention for Patients With Coronary and Other Vascular Disease: 2001 Update
Goals Intervention Recommendations
Smoking:
Goal
complete cessation
Assess tobacco use. Strongly encourage patient and family to stop smoking and to avoid secondhand smoke. Provide
counseling, pharmacological therapy, including nicotine replacement and buproprion, and formal smoking cessation
programs as appropriate.
BP control:
Goal
,140/90 mm Hg or
,130/85 mm Hg if
heart failure or renal
insufficiency
,130/80 mm Hg if
diabetes
Initiate lifestyle modification (weight control, physical activity, alcohol moderation, moderate sodium restriction, and
emphasis on fruits, vegetables, and low-fat dairy products) in all patients with blood pressure $130 mm Hg systolic or
80 mm Hg diastolic.
Add blood pressure medication, individualized to other patient requirements and characteristics (ie, age, race, need for
drugs with specific benefits) if blood pressure is not ,140 mm Hg systolic or 90 mm Hg diastolic or if blood pressure is
not ,130 mm Hg systolic or 85 mm Hg diastolic for individuals with heart failure or renal insufficiency (,80 mm Hg
diastolic for individuals with diabetes).
Lipid management:
Primary goal
LDL ,100 mg/dL
Start dietary therapy in all patients (,7% saturated fat and ,200 mg/d cholesterol) and promote physical activity and
weight management. Encourage increased consumption of omega-3 fatty acids. Assess fasting lipid profile in all patients,
and within 24 hr of hospitalization for those with an acute event. If patients are hospitalized, consider adding drug
therapy on discharge. Add drug therapy according to the following guide:
LDL ,100 mg/dL
(baseline or on-treatment)
Further LDL-lowering therapy not
required
Consider fibrate or niacin (if low
HDL or high TG)
LDL 100–129 mg/dL
(baseline or on-treatment)
Therapeutic options:
Intensify LDL-lowering therapy
(statin or resin*)
Fibrate or niacin (if low HDL or
high TG)
Consider combined drug therapy
(statin1fibrate or niacin) (if low
HDL or high TG)
LDL $130 mg/dL
(baseline or on-treatment)
Intensify LDL-lowering therapy
(statin or resin*)
Add or increase drug therapy
with lifestyle therapies
Lipid management:
Secondary goal
If TG $200 mg/dL,
then non-HDL† should
be ,130 mg/dL
If TG $150 mg/dL or HDL ,40 mg/dL: Emphasize weight management and physical activity. Advise smoking cessation.
If TG 200–499 mg/dL: Consider fibrate or niacin after LDL-lowering therapy*
If TG $500 mg/dL: Consider fibrate or niacin before LDL-lowering therapy*
Consider omega-3 fatty acids as adjunct for high TG
Physical activity:
Minimum goal
30 minutes 3 to 4 days
per week
Optimal daily
Assess risk, preferably with exercise test, to guide prescription.
Encourage minimum of 30 to 60 minutes of activity, preferably daily, or at least 3 or 4 times weekly (walking, jogging,
cycling, or other aerobic activity) supplemented by an increase in daily lifestyle activities (eg, walking breaks at work,
gardening, household work). Advise medically supervised programs for moderate- to high-risk patients.
Weight management:
Goal
BMI 18.5–24.9 kg/m2
Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and waist circumference
to therapy.
Start weight management and physical activity as appropriate. Desirable BMI range is 18.5–24.9 kg/m2.
When BMI $25 kg/m2, goal for waist circumference is #40 inches in men and #35 inches in women.
Diabetes management:
Goal
HbA1c ,7%
Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c.
Treatment of other risks (eg, physical activity, weight management, blood pressure, and cholesterol management).
Antiplatelet agents/
anticoagulants:
Start and continue indefinitely aspirin 75 to 325 mg/d if not contraindicated. Consider clopidogrel 75 mg/d or warfarin if
aspirin contraindicated. Manage warfarin to international normalized ratio52.0 to 3.0 in post-MI patients when clinically
indicated or for those not able to take aspirin or clopidogrel.
ACE inhibitors: Treat all patients indefinitely post MI; start early in stable high-risk patients (anterior MI, previous MI, Killip class II [S3
gallop, rales, radiographic CHF]). Consider chronic therapy for all other patients with coronary or other vascular disease
unless contraindicated.
b-Blockers: Start in all post-MI and acute ischemic syndrome patients. Continue indefinitely. Observe usual contraindications. Use as
needed to manage angina, rhythm, or blood pressure in all other patients.
BP indicates blood pressure; TG, triglycerides; BMI, body mass index; HbA1c, major fraction of adult hemoglobin; MI, myocardial infarction; and CHF, congestive
heart failure.
*The use of resin is relatively contraindicated when TG .200 mg/dL.
†Non-HDL cholesterol5total cholesterol minus HDL cholesterol.
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